Yuan Yuan, Ji Shangli, Song Yali, Che Zhaodi, Xiao Lu, Tang Shibo, Xiao Jia
Aier School of Ophthalmology, Central South University, Changsha, Hunan Province, China.
Changsha Aier Eye Hospital, Changsha, Hunan Province, China.
Neural Regen Res. 2024 Oct 1;19(10):2310-2320. doi: 10.4103/1673-5374.391303. Epub 2023 Dec 21.
JOURNAL/nrgr/04.03/01300535-202410000-00032/figure1/v/2024-02-06T055622Z/r/image-tiff Diabetic eye disease refers to a group of eye complications that occur in diabetic patients and include diabetic retinopathy, diabetic macular edema, diabetic cataracts, and diabetic glaucoma. However, the global epidemiology of these conditions has not been well characterized. In this study, we collected information on diabetic eye disease-related research grants from seven representative countries--the United States, China, Japan, the United Kingdom, Spain, Germany, and France--by searching for all global diabetic eye disease journal articles in the Web of Science and PubMed databases, all global registered clinical trials in the ClinicalTrials database, and new drugs approved by the United States, China, Japan, and EU agencies from 2012 to 2021. During this time period, diabetic retinopathy accounted for the vast majority (89.53%) of the 2288 government research grants that were funded to investigate diabetic eye disease, followed by diabetic macular edema (9.27%). The United States granted the most research funding for diabetic eye disease out of the seven countries assessed. The research objectives of grants focusing on diabetic retinopathy and diabetic macular edema differed by country. Additionally, the United States was dominant in terms of research output, publishing 17.53% of global papers about diabetic eye disease and receiving 22.58% of total citations. The United States and the United Kingdom led international collaborations in research into diabetic eye disease. Of the 415 clinical trials that we identified, diabetic macular edema was the major disease that was targeted for drug development (58.19%). Approximately half of the trials (49.13%) pertained to angiogenesis. However, few drugs were approved for ophthalmic (40 out of 1830; 2.19%) and diabetic eye disease (3 out of 1830; 0.02%) applications. Our findings show that basic and translational research related to diabetic eye disease in the past decade has not been highly active, and has yielded few new treatment methods and newly approved drugs.
《期刊》/nrgr/04.03/01300535 - 202410000 - 00032/图1/v/2024 - 02 - 06T055622Z/图像 - tiff 糖尿病眼病是指糖尿病患者发生的一组眼部并发症，包括糖尿病视网膜病变、糖尿病黄斑水肿、糖尿病性白内障和糖尿病性青光眼。然而，这些疾病的全球流行病学特征尚未得到很好的描述。在本研究中，我们通过检索科学网（Web of Science）和PubMed数据库中所有关于全球糖尿病眼病的期刊文章、ClinicalTrials数据库中所有全球注册的临床试验，以及2012年至2021年期间美国、中国、日本和欧盟机构批准的新药，收集了来自七个代表性国家——美国、中国、日本、英国、西班牙、德国和法国——与糖尿病眼病相关的研究资助信息。在此期间，在2288项获得资助用于研究糖尿病眼病的政府研究资助中，糖尿病视网膜病变占绝大多数（89.53%），其次是糖尿病黄斑水肿（9.27%）。在所评估的七个国家中，美国对糖尿病眼病的研究资助最多。关注糖尿病视网膜病变和糖尿病黄斑水肿的资助研究目标因国家而异。此外，美国在研究产出方面占主导地位，发表了全球17.53%的关于糖尿病眼病的论文，并获得了22.58%的总引用量。美国和英国在糖尿病眼病研究的国际合作中处于领先地位。在我们确定的415项临床试验中，糖尿病黄斑水肿是药物开发的主要针对疾病（58.19%）。大约一半的试验（49.13%）与血管生成有关。然而，很少有药物被批准用于眼科（1830种中有40种；2.19%）和糖尿病眼病（1830种中有3种；0.02%）应用。我们的研究结果表明，过去十年中与糖尿病眼病相关的基础研究和转化研究并不活跃，几乎没有产生新的治疗方法和新批准的药物。
